ICCM Key Statistics, Chart & Performance
The current stock price of ICCM is 0.6642 USD. In the past month the price decreased by -6.45%. In the past year, price decreased by -37.93%.
ICCM Latest News, Press Relases and Analysis
ICCM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.14 | 218.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.99 | 192.25B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.38 | 137.24B | ||
| SYK | STRYKER CORP | 26.89 | 135.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.93 | 57.34B | ||
| IDXX | IDEXX LABORATORIES INC | 55.84 | 56.23B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.33 | 48.21B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.29 | 38.25B | ||
| RMD | RESMED INC | 25.48 | 36.82B | ||
| DXCM | DEXCOM INC | 36 | 26.12B | ||
| PODD | INSULET CORP | 64.7 | 20.80B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.32 | 18.15B |
Related stock screener links
About ICCM
Company Profile
IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Company Info
ICECURE MEDICAL LTD
7 Ha'eshel St., PO Box 3163
CAESAREA IL
CEO: EYAL SHAMIR
Employees: 65
Phone: 97246230333
ICECURE MEDICAL LTD / ICCM FAQ
What does ICCM do?
IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Can you provide the latest stock price for ICECURE MEDICAL LTD?
The current stock price of ICCM is 0.6642 USD. The price decreased by -3.91% in the last trading session.
What is the dividend status of ICECURE MEDICAL LTD?
ICCM does not pay a dividend.
What is the ChartMill technical and fundamental rating of ICCM stock?
ICCM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ICECURE MEDICAL LTD (ICCM)?
ICECURE MEDICAL LTD (ICCM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is the employee count for ICCM stock?
ICECURE MEDICAL LTD (ICCM) currently has 65 employees.
What is the ownership structure of ICECURE MEDICAL LTD (ICCM)?
You can find the ownership structure of ICECURE MEDICAL LTD (ICCM) on the Ownership tab.
ICCM Technical Analysis
ICCM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ICCM. The financial health of ICCM is average, but there are quite some concerns on its profitability.
ICCM Financial Highlights
Over the last trailing twelve months ICCM reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 8.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.41% | ||
| ROE | -164.3% | ||
| Debt/Equity | 0 |
ICCM Forecast & Estimates
8 analysts have analysed ICCM and the average price target is 3.19 USD. This implies a price increase of 379.9% is expected in the next year compared to the current price of 0.6642.
For the next year, analysts expect an EPS growth of 26.9% and a revenue growth 5.29% for ICCM